Indusatumab vedotin
Based on 1 Customer Validation
Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 96.37%
- CAS No.: 1514889-12-3
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Guanylate cyclase (GCC)[1]
Indusatumab vedotin (0.4-25 μg/mL; 72 h) causes antiproliferative effects in pancreatic cancer cell lines[1].
Indusatumab vedotin (12.5 μg/mL; 24 h) arrests cell cycle at G2/M in MIA PaCa-2 and PANC-1 cells, and causes the P-Hitone H3 production[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MIA PaCa-2 and PANC-1 cells
-
Concentration:12.5 μg/mL
-
Incubation Time:24 hours
-
Result:Increased the protein level of P-Hitone H3, indicating tubulin polymerization.
-
Cell Line:MIA PaCa-2 and PANC-1 cells
-
Concentration:12.5 μg/mL
-
Incubation Time:24 hours
-
Result:Decreased cell number in G1 phase and caused an induction of a G2/M arrest.
-
Cell Line:GCC Knock cells and Pancreatic cancer cell lines: L3.6, MIA PaCa-2, Panc 03.27, Panc 05.04 and Panc 02.03
-
Concentration:0.4 μg/mL, 0.8 μg/mL, 1.6 μg/mL, 3.1 μg/mL, 6.3 μg/mL, 12.5 μg/mL, and 25 μg/mL
-
Incubation Time:72 hours
-
Result:Inhibited the cell viability of pancreatic cancer cells, but not GCC Knock cells.
Indusatumab vedotin shows strongly correlated biological activity with exposure in mice bearing one of six different xenograft models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pancreas Explant Xenograft Model in Mouse[1]
-
Dosage:10 mg/kg
-
Administration:Intravenous injection in tail; once weekly for 17-50 days
-
Result:Inhibited the volume growth of 10 types tumors significantly.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1514889-12-3
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Indusatumab vedotin]
-
Synonyms
MLN0264; TAK-264
-
Livraison
Shipping with dry ice.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Indusatumab vedotin Related Classifications
HY-P99662 Related Classifications
Powered by Bioz